World Vaccine Congress Brochure Available

  The World Vaccine Congress Washington is now in its 15th year, and things look a little different to previous years. ‘So why the change?’ I hear you ask… In my previous role, we produced very focused agendas and ran two-day events specifically on that area. This would be as niche as talking only about foundations for deep water offshore …

New Vaccine Provides Greater Protection than BCG Against Both Tuberculosis and Leprosy

Research headed by UCLA has found that a variation of the BCG vaccine offers stronger protection against the diseases Both tuberculosis and leprosy often occur together, and leprosy usually only occurs in places where tuberculosis occurs. Most infants are vaccinated against the two diseases with the Bacille Calmette-Guerin vaccination, which has been used for over a century now. However this …

Exclusive vaccine delivery interview with Dr Chantal Pichon, University of Orleans and CNRS

The 15th World Vaccine Congress on 13 – 15 October in Brussels is just a few weeks away and I recently sat down with one of our key speakers, Dr Chantal Pichon (Professor, University of Orleans and CNRS Center for Molecular Biophysics) for a short interview. Dr Pichon will be discussing her research in Histidylated-based nanoparticles for mRNA vaccines delivery. …

Top 4 Challenges for Vaccine Manufacturers

Recently we undertook the research for the 15th annual World Vaccine Congress, and so asked what the biggest challenges are for each segment of the market. When we spoke to vaccine manufacturers, these came up as the 4 biggest issues:   1)      Adjuvants Adjuvants are often lauded as the way forward to make vaccines more effective, but given how new …

GHTC report warns against R&D cuts in US

Cuts to the R&D programmes in the United States (US) could have a devastating impact on a number of important healthcare initiatives, including the world's first malaria vaccine. The latest report produced by the Global Health Technologies Coalition (GHTC) states that "cutting funding for global health and R&D programs would barely make a dent in reducing the US federal deficit …

Presentation download: Development of a recombinant protective antigen (rPA) based anthrax vaccine

Thomas Fuerst, Executive Vice President, Chief Scientific Officer from PharmAthene joined us at the World Vaccine Congress 2012 in Washington to give details about the development of a recombinant protective antigen (rPA) based anthrax vaccine. In his presentation he detailed: · Background Information – Next Generation Vaccine · Development of a Robust Manufacturing Platform · Analytical Methods for Purity and …

Case study: Purification of Group C meningococcal polysaccharide for a conjugate vaccine

R&D is a staple of the vaccine industry. Each new discovery is another step towards the global eradiation of another disease. Shwu-Maan Lee, Director, Technical Affairs, Baxter BioScience joined us at the World Vaccine Congress in Washington 2012 to give details on the Group c meningococcal polysaccharide for a conjugate vaccine. In 2000, the NeisVac-C was licensed in 38 countries …

The ViroCyt Virus Counter and the ViroPrep Sample Cleanup System

InDevR develops and commercializes innovative instrumentation and assays for the rapid detection, quantification and identification of viruses and other pathogens. The ViroCyt Virus Counter is a revolutionary instrument developed explicitly for virus quantification: Delivers a quantitative measurement of the number of intact virus particles per mL within minutes Provides a time- and cost-effective alternative to plaque titer, TCID50/EID50, SRID, HA …